News of the day
Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
DURHAM, N.C.-- November 4, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials.
more
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon (October 2009)
LOUISVILLE, Ky., Oct. 23, 2009 -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc. (NYSE: ACL). The agreements provide Alcon with a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. The agreements also provide for...
more
SynergEyes Awarded U.S. Patent
Carlsbad, CA (October 7, 2009) - SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, announced today that it has received an additional patent from the U.S. Patent and Trademark Office. The new patent pertains to SynergEyes' hybrid contact lens bonding technology and manufacturing processes. The new patent complements prior patents awarded SynergEyes for its high Dk hybrid contact lens design. The patent is for a hybrid contact lens with intermediate zones that facilitate chemical...
more
Industry news search
Recent news
To keep up to date with news from this category use our 
Carl Zeiss Meditec Launches "Eye On OCT"
DUBLIN/California/USA, JENA/Germany, 06.10.2009 - A new online optical coherence tomography (OCT) resource for the eye care industry was launched by Carl Zeiss Meditec during the Retina Congress 2009 convention in New...
CombinatoRx-Derived Combination Drug Candidate, Prednisporin, Acquired by Sanofi-Aventis Through Proposed Acquisition of Fovea Pharmaceuticals
CAMBRIDGE, Mass.--Oct. 5, 2009-- CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A...
All rights reserved. Terms and Conditions | Contact us
